Contraindications to insertion of etonogestrel contraceptive implant
- Consent not given.
- Individuals under 16 years of age and assessed as not competent using Fraser Guidelines.
- Individuals 16 years of age and over and assessed as lacking capacity to consent.
- Known hypersensitivity to the active ingredient or to any constituent of the product - see Summary of Product Characteristics (SPC)
- Unexplained vaginal bleeding (suspicious of serious condition) before evaluation
- Acute porphyria
Cardiovascular Disease
- Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic first attack only if these events first occurred during use of the etonogestrel implant.
Cancers
- Current or past history of breast cancer.
Gastro-intestinal conditions
- Severe decompensated cirrhosis.
- Benign liver tumour (hepatocellular adenoma).
- Malignant liver tumour (hepatocellular carcinoma).
Interacting medicines
- Individuals using enzyme-inducing drugs/herbal products or within 28 days of stopping them.
Interacting medicines other than enzyme inducers – see current British National Formulary (BNF) or individual product SPC
Reference:
- Patient Group Direction (PGD) (NHS Specialist Pharmacy Service). Insertion of etonogestrel (e.g. Nexplanon®) 68mg subdermal implant for contraception . (Accessed 17th March 2021)
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.